Roche Laboratories informed healthcare professionals of changes to the WARNINGS and ADVERSE REACTIONS sections of the CellCept prescribing information. The changes are based on postmarketing data regarding cases of Progressive Multifocal Leukoencephalopathy (PML) in patients treated with CellCept. 

Read the entire 2008 MedWatch Safety Summary, including the manufacturer's Dear Healthcare Professional Letter regarding this issue at: 
http://www.fda.gov/medwatch/safety/2008/safety08.htm#mycophenolate 
 
The letter may be viewed at: http://rocheusa.com/products/cellcept/CellceptLetterPML_May2008.pdf


Zynchros Pharmacy Services